Paliperidone +pharma, (Paliperidone Palmitate)

Paliperidone palmitate is an atypical antipsychotic that works within the dopamine‑serotonin pathway to manage chronic psychotic disorders.

• Schizophrenia: helps control acute psychotic episodes and reduces risk of relapse in adults.
• Schizoaffective disorder: stabilises mood and psychotic symptoms when used as part of a comprehensive treatment plan.
• Maintenance therapy: provides sustained symptom control with monthly or quarterly dosing, decreasing the need for daily oral medication.

• Paliperidone palmitate is a pro‑drug of paliperidone that slowly releases the active molecule after intramuscular injection. The active compound antagonises dopamine D2 and serotonin 5‑HT2A receptors, modulating neurotransmission in brain pathways implicated in psychosis and mood regulation.

Paliperidone palmitate may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

• Injection site pain or erythema
• Headache
• Drowsiness or somnolence
• Weight gain
• Restlessness (akathisia)
• Constipation

Serious or Rare Side Effects

• Neuroleptic malignant syndrome
• Tardive dyskinesia
• Severe orthostatic hypotension
• Hyperglycaemia or new‑onset diabetes
• Seizures
• Elevated prolactin leading to galactorrhoea or menstrual disturbances

When prescribing Paliperidone palmitate, clinicians should consider patient‑specific factors and monitor for adverse events.

• Cardiovascular assessment: evaluate for history of arrhythmias or QT prolongation.
• Metabolic monitoring: check blood glucose and lipid profile regularly.
• Movement disorders: observe for signs of tardive dyskinesia or akathisia.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed.
• Drug interactions: review concomitant medications for CYP‑related effects.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Paliperidone palmitate can interact with several drug classes; careful review is required before co‑administration.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce plasma concentrations.
• QT‑prolonging agents (e.g., quinidine, haloperidol): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation.
• Antihypertensives: additive orthostatic hypotension.
• Anticholinergic drugs: may exacerbate constipation.
• CYP2D6 inhibitors (e.g., fluoxetine): modestly increase paliperidone levels.
• Herbal supplements such as St. John’s wort: potential enzyme induction.